Rep. Katie Porter (D-Calif.)--minus her "Whiteboard of Justice"--speaks at the U.S. Capitol on December 19, 2019. (Photo: Alex Wong/Getty Images)
'You Lie': Katie Porter Wields 'Whiteboard of Justice' While Grilling Pharma CEO on Price Hikes
"You're spending all this money to make sure you make money rather than spending money to... help patients," the California congresswoman told AbbVie's Richard Gonzalez.
U.S. lawmakers on Tuesday took the CEO of the maker of the world's bestselling drug to task for high product prices, with Rep. Katie Porter using her famed "Whiteboard of Justice" to demonstrate what she called "the Big Pharma fairy tale" that pharmaceutical research and development costs justify perpetual price hikes.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices. But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
--Rep. Katie Porter
Members of the House Oversight Committee grilled AbbVie CEO Richard Gonzalez--whose total compensation topped $24 million last year (pdf)--about the reasons for increasing the price of its top-selling drug Humira to $77,000 for a year's supply.
Humira (adalimumab) is an immunosuppressant used to treat a wide range of inflammatory conditions including arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Last year, Humira sales neared $20 billion, making it by far the world's bestselling pharmaceutical drug.
In January, Fortune reported AbbVie would raise the price of Humira by 7.4%. Why the increase? Drugmakers often claim higher prices are needed to fund research and development. AbbVie spent a total of $2.45 billion on R&D from 2013 to 2018.
Porter (D-Calif.) pointed out that the company spends nearly double that--$4.7 billion--annually on advertising.
When Porter asked Gonzalez how much the company compensates its executives, the CEO said, "About $60 million a year."
"Try $334 [million] on for size," Porter shot back.
Noting that AbbVie spent around $50 billion on cumulative stock buybacks and dividends from 2013 to 2018, Porter then told Gonzalez: "You're spending all this money to make sure you make money rather than spending money to invest in [and] develop drugs and help patients with affordable, lifesaving drugs."
"You lie to patients when you charge them twice as much for an unimproved drug, and then you lie to policymakers when you tell us that R&D justifies those price increases," Porter asserted.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices," she said. "But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
"The fact [is] that you're not honest about that with patients and policymakers--that you're feeding us lies that we must pay astronomical prices to get 'innovative' treatments," added Porter. "The American people, the patients, deserve so much better."
Urgent. It's never been this bad.
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission from the outset was simple. To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It’s never been this bad out there. And it’s never been this hard to keep us going. At the very moment Common Dreams is most needed and doing some of its best and most important work, the threats we face are intensifying. Right now, with just four days to go in our Spring Campaign, we are not even halfway to our goal. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Can you make a gift right now to make sure Common Dreams not only survives but thrives? There is no backup plan or rainy day fund. There is only you. —Craig Brown, Co-founder |
U.S. lawmakers on Tuesday took the CEO of the maker of the world's bestselling drug to task for high product prices, with Rep. Katie Porter using her famed "Whiteboard of Justice" to demonstrate what she called "the Big Pharma fairy tale" that pharmaceutical research and development costs justify perpetual price hikes.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices. But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
--Rep. Katie Porter
Members of the House Oversight Committee grilled AbbVie CEO Richard Gonzalez--whose total compensation topped $24 million last year (pdf)--about the reasons for increasing the price of its top-selling drug Humira to $77,000 for a year's supply.
Humira (adalimumab) is an immunosuppressant used to treat a wide range of inflammatory conditions including arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Last year, Humira sales neared $20 billion, making it by far the world's bestselling pharmaceutical drug.
In January, Fortune reported AbbVie would raise the price of Humira by 7.4%. Why the increase? Drugmakers often claim higher prices are needed to fund research and development. AbbVie spent a total of $2.45 billion on R&D from 2013 to 2018.
Porter (D-Calif.) pointed out that the company spends nearly double that--$4.7 billion--annually on advertising.
When Porter asked Gonzalez how much the company compensates its executives, the CEO said, "About $60 million a year."
"Try $334 [million] on for size," Porter shot back.
Noting that AbbVie spent around $50 billion on cumulative stock buybacks and dividends from 2013 to 2018, Porter then told Gonzalez: "You're spending all this money to make sure you make money rather than spending money to invest in [and] develop drugs and help patients with affordable, lifesaving drugs."
"You lie to patients when you charge them twice as much for an unimproved drug, and then you lie to policymakers when you tell us that R&D justifies those price increases," Porter asserted.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices," she said. "But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
"The fact [is] that you're not honest about that with patients and policymakers--that you're feeding us lies that we must pay astronomical prices to get 'innovative' treatments," added Porter. "The American people, the patients, deserve so much better."
U.S. lawmakers on Tuesday took the CEO of the maker of the world's bestselling drug to task for high product prices, with Rep. Katie Porter using her famed "Whiteboard of Justice" to demonstrate what she called "the Big Pharma fairy tale" that pharmaceutical research and development costs justify perpetual price hikes.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices. But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
--Rep. Katie Porter
Members of the House Oversight Committee grilled AbbVie CEO Richard Gonzalez--whose total compensation topped $24 million last year (pdf)--about the reasons for increasing the price of its top-selling drug Humira to $77,000 for a year's supply.
Humira (adalimumab) is an immunosuppressant used to treat a wide range of inflammatory conditions including arthritis, Crohn's disease, psoriasis, and ulcerative colitis. Last year, Humira sales neared $20 billion, making it by far the world's bestselling pharmaceutical drug.
In January, Fortune reported AbbVie would raise the price of Humira by 7.4%. Why the increase? Drugmakers often claim higher prices are needed to fund research and development. AbbVie spent a total of $2.45 billion on R&D from 2013 to 2018.
Porter (D-Calif.) pointed out that the company spends nearly double that--$4.7 billion--annually on advertising.
When Porter asked Gonzalez how much the company compensates its executives, the CEO said, "About $60 million a year."
"Try $334 [million] on for size," Porter shot back.
Noting that AbbVie spent around $50 billion on cumulative stock buybacks and dividends from 2013 to 2018, Porter then told Gonzalez: "You're spending all this money to make sure you make money rather than spending money to invest in [and] develop drugs and help patients with affordable, lifesaving drugs."
"You lie to patients when you charge them twice as much for an unimproved drug, and then you lie to policymakers when you tell us that R&D justifies those price increases," Porter asserted.
"The Big Pharma fairy tale is one of groundbreaking R&D that justifies astronomical prices," she said. "But the pharma reality is that you spend most of your company's money making money for yourself and your shareholders."
"The fact [is] that you're not honest about that with patients and policymakers--that you're feeding us lies that we must pay astronomical prices to get 'innovative' treatments," added Porter. "The American people, the patients, deserve so much better."